Evidence map›Paper›PMID 32462055›Full record

ArticleJournal of cancer research and therapeutic oncology2020

Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice.

Feng Su, Anantharamaiah Gm, Mayakonda N Palgunachari, C Roger White, Holly Stessman, Yanyuan Wu, Jay Vadgama, Richard Pietras, Dorothy Nguyen, Srinivasa T Reddy and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and therapeutic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Feng SuDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, the University of California at Los Angeles, Los Angeles, CA 90095, USA.
Anantharamaiah GmDepartment of Medicine, the University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Mayakonda N PalgunachariDepartment of Medicine, the University of Alabama at Birmingham, Birmingham, AL 35294, USA.
C Roger WhiteDepartment of Medicine, the University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Holly StessmanDepartment of Pharmacology, Creighton University Medical School, Omaha, NE 68178, USA.
Yanyuan WuDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
Jay VadgamaDepartment of Internal Medicine, Charles Drew University, Los Angeles, CA 90059, USA.
Richard PietrasJonsson Comprehensive Cancer Center, the University of California at Los Angeles, Los Angeles, CA 90095, USA.
Dorothy NguyenDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, the University of California at Los Angeles, Los Angeles, CA 90095, USA.
Srinivasa T ReddyDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, the University of California at Los Angeles, Los Angeles, CA 90095, USA.
Robin Farias-EisnerDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, the University of California at Los Angeles, Los Angeles, CA 90095, USA.
University of Alabama at Birmingham · USUniversity of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
Supporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI VADGAMA, JAYDUTT V. · 2009 to 2022
$19.7M
Training and Mentoring ProgramsU54CA143930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PIETRAS, RICHARD JOSEPH · 2009 to 2020
$7.5M
NCI NIH HHS P30 CA016042NCI NIH HHS U54 CA143930NCI NIH HHS U54 CA143931
6 · The paper itself

Abstract

A growing body of literature supports the role of apolipoproteins present in HDL in the treatment of pro-inflammatory diseases including cancer. We examined whether bovine HDL (bHDL) and three dual-domain peptides, namely AEM-28 and its analog AEM-28-2, and HM-10/10, affect tumor growth and development in mouse models of ovarian and colon cancer. We demonstrate that bHDL inhibits mouse colorectal cancer cell line CT26-mediated lung tumor development, and mouse ovarian cancer cell line ID8-mediated tumor burden. We also demonstrate that, although to different degrees, dual-domain peptides inhibit cell viability of mouse and human ovarian and colon cancer cell lines, but not that of normal human colonic epithelial cells or NIH3T3 mouse fibroblasts. Dual-domain peptides administered subcutaneously or in a chow diet decrease CT26 cell-mediated tumor burden, tumor growth, and tumor dissemination in BALB/c mice. Plasma levels of lysophosphatidic acid (LPA) are significantly reduced in mice that received bHDL and the dual-domain peptides, suggesting that reduction by effecting accumulation and/or synthesis of pro-inflammatory lipids may be one of the mechanisms for the inhibition of tumor development by bHDL and the dual-domain peptides. Our studies suggest that therapeutics based on apolipoproteins present in HDL may be novel agents for the treatment of epithelial adenocarcinomas of the ovary and colon.

Indexed as

Cancer TherapeuticsColon CancerHDLLPAMimetic PeptidesOvarian Cancer

Identifiers

PMID32462055
PMCPMC7252215
OpenAlexW3032027926

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.